NCT07516093Phase 3Recruiting

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Study sponsor: Nurix Therapeutics, Inc. · NRIX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-10Estimated
Enrollment · participants620Estimated
Source updated2026-08-31Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Progression-free survival (PFS) as assessed by Independent Review Committee (IRC). After: Measure: Progression-free survival (PFS) as assessed by Independent Review Committee (IRC) Measure: Objective response rate (ORR) without partial response with lymphocytosis (PR-L) as assessed by IRC.

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source